anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2-9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichia colipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11-13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care.
SOC Tissue Biopsy. Occurs at months 0, 3-6, and 6-12.
Heart failure (HF) is a complex chronic condition characterized by structural and functional impairments. The differentiation of endothelial cells into myofibroblasts (EndoMT) in response to cardiac fibrosis is controversial, and the relative contribution of endothelial plasticity remains to be explored. Single-cell RNA sequencing was used to identify endothelial cells undergoing fibrotic differentiation within 2 weeks of transverse aortic constriction (TAC). This subset of endothelial cells transiently expressed fibrotic genes but had low expression of alpha-smooth muscle actin, indicating a non-canonical EndoMT, which we named a transient fibrotic-like phenotype (EndoFP). The role of EndoFP in pathological cardiac remodeling may be correlated with increased levels of osteopontin. Cardiomyocytes and fibroblasts co-cultured with EndoFP exhibited heightened pro-hypertrophic and pro-fibrotic effects. Mechanistically, we found that the upregulated expression of insulin-like growth factor-binding protein 5 may be a key mediator of EndoFP-induced cardiac dysfunction. Furthermore, our findings suggested that Rab5a is a novel regulatory gene involved in the EndoFP process. Our study suggests that the specific endothelial subset identified in TAC-induced pressure overload plays a critical role in the cellular interactions that lead to cardiac fibrosis and hypertrophy. Additionally, our findings provide insight into the mechanisms underlying EndoFP, making it a potential therapeutic target for early heart failure.
The present disclosure provides the complete primary amino acid, and underlying DNA, sequence for the 47-kilodalton surface immunogen of Treponema pallidum, subsp. pallidum. The-sequence was obtained by using a combined strategy of DNA sequencing of the cloned gene as well as confirmatory N-terminal amino acid sequencing of the native antigen. An open reading frame corresponding to the 47-kDa antigen was comprised of 367 amino acid codons, which gave rise to a calculated molecular weight for the corresponding antigen of about 40,701. Also disclosed are methods for preparing variant and mutant molecules having biologically similar attributes, as well as methods for preparing particular antigenic/immunogenic subportions of the 47-kDa protein. In particular aspects, antigenic/immunogenic subportions are identified by hydrophilicity analysis of the protein sequence. The 47-kDa antigen and antigenic subportions of the present invention can be used both as antigens in the detection.of clinical materials having anti-47-kDa antibodies therein, as well as in the preparation of vaccines for use in connection with promoting an immune state in vaccinated individuals. Also disclosed are DNA sequences which may be useful both in the preparation of second generation antigens, and as hybridization probes in the detection of pathogenic T. pallidum in clinical samples. Particular methods and embodiments are also disclosed which allow greatly improved recombinant DNA production of the 47-kDa antigen, including placement of the gene under the control of the T7 RNA polymerase promoter.
<P>PROBLEM TO BE SOLVED: To provide a medical care system for having daily biological information sensing data checked by a specialist without visiting a hospital and capable of having medicines prescribed and delivered.  <P>SOLUTION: A patient medical care sensor device, a medical care institution, and a pharmacy are connected via a network. The patient medical care sensor device is carried by a patient, or the information sensed by a medical care sensor at home is transmitted together with the information specifying the patient. A medical institution comprises a sensing database for receiving the sensed information and the information specifying the patient and storing the information for every patient, diagnosis of the patient as the subject of sensing by the medical care sensor, based on the sensed data without requiring the patient to come to the hospital, a medical care scheduler for storing the checking time and date, a means of presenting the sensed data to a doctor in charge of the patient on the stored time and date, a dosing database prescribed for the every patient by the doctor in charge, and a means of transmitting the prescription together with the address of the patient. The pharmacy comprises means of receiving the prescription and the information on the patient, and delivering the medicine based on the prescription to the address of the patient.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Aβ1-42 (amyloid beta) oligomers, the major neurotoxic culprits in Alzheimer's disease, initiate early pathophysiological events, including neuronal hyperactivity, that underlie aberrant network activity and cognitive impairment. Although several synaptotoxic effects have been extensively studied, neuronal hyperexcitability, which may also contribute to cognitive deficits, is not fully understood. Here, we found several adverse effects of in vivo injection of Aβ1-42 oligomers on contextual memory and intrinsic properties of CA1 pyramidal neurons. Male rats underwent behavioral and electrophysiological studies 1 week after microinjections into the dorsal CA1 region, followed by histological analysis. After 1 week, Aβ1-42 oligomers impaired contextual learning without affecting basic physiological functions and triggered training-induced neuronal excitability. Furthermore, riluzole, a persistent sodium current (INaP) blocker, dose-dependently reduced Aβ1-42 oligomer-induced hyperexcitability. Congo red staining, which detects insoluble amyloid deposits, further identified labeling of CA1 pyramidal neurons while immunohistochemistry with lecanemab, which detects soluble Aβ oligomers, revealed immunoreactivity of both pyramidal and non-pyramidal cells in the target area. Therefore, our study suggests that a single injection of Aβ1-42 oligomers resulted in contextual memory deficits along with concomitant neuronal hyperexcitability and amyloid deposition in the CA1 region after 1 week.
PURPOSE:To specifically adsorption-remove a physiologically active substance such as a nucleic acid charged in negative on an insoluble carrier having immobilized a chemotherapeutic agent by a photochemical reaction, and further to determine the physiologically active substance bonded to the insoluble carrier. CONSTITUTION:The surface of an insoluble carrier is coated with an azide group- containing polymer (e.g. azidostyrene), a low-molecular compound (e.g. a bisazide compound), etc., and then a chemotherapeutic agent to be immobilized and irradiated with light rays at longer wavelength than 320nm. Consequently the chemotherapeutic agent is readily and firmly bonded to the insoluble carrier without losing activity of the chemotherapeutic agent. The carrier bonded to the chemotherapeutic agent by covalent bond is produced by gene recombination technology and a physiologically active substance charged in negative is adsorbed on the carrier and safely and surely separated and removed. Further, the physiologically active substance charged in negative can be determined by using the insoluble carrier.
PURPOSE:To obtain bar cosmetic inexpensively and accurately,by setting a spacer in the opening of a molding hole, injecting a molten cosmetic material through the spacer to the hole, cooling and solidifying it, attaching the spacer to a pushing container, drawing it out from the molding hole. CONSTITUTION:The molding hole 2 is shaved and made in the dug mold 1 and the cylindrical spacer 7 is immovably engaged with the opening of the molding hole 2. A molten cosmetic material is injected through the nozzle 6 to the hole until it reaches the spacer 7, cooled and solidified. The dug mold 1 consists of a metal haivng high thermal conductivity, and the cooling paths 3 are preferably dug around the molding hole 2. Since a cosmetic is set on the spacer 7, a drawing force is applied to the spacer 7, so that the cosmetic 8 can be extracted without being damaged. After the spacer 7 is joined to a pushing container, the cosmetic is preferably extracted from the molding hole. A lipstick etc. can be molded uniformly and accurately.
Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
The low-level laser diode treatment of 810 nm will be performed using a commercially available diode laser device. The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode starting at a distance of 5-6 mm away from the hypersensitive tooth area and slowly approaching within a distance of 2-3mm in a scanning motion covering the entire hypersensitive tooth area for a period of 30 seconds to 1 minute.
The invention relates to a non-steroidal anti-inflammatory demulcent drug, which is a diclofenac epolamine gel preparation for relieving moderate pain in muscles, soft tissues and articulations. The gel preparation adopts 0.1-8.0 percent (weight percentage) of diclofenac epolamine as a main activated ingredient, 0-20 percent of grease, 0-5 percent of surfactant, 5-20 percent of cosolvent, a pH regulator, 5-20 percent of bacteriostat, 0.5-2.0 percent of gel substrate, etc. and purified water. PH value of the preparation is 6.0-8.0. The invention also provides a preparation method of the gel. The gel preparation of the invention has the advantages of good stability and good skin coupling effect, and can promote absorption of the skin to the drug and improve bioavailability and curative effect; at the same time, the substrate has stable property and no irritation to the skin, can be easily smeared and washed, has no greasiness, is beneficial to releasing of drug, especially water solubledrug and has good safety and clinical practicability.
PURPOSE:To facilitate filling and to prevent the generation of outflow by blood or body fluid and leakage after sture, by mixing powdery tetracalcium phosphate and powdery calcium phosphate having a specific Ca/P mol ratio with a hydroxyapatite granule in a specific ratio. CONSTITUTION:The average particle size of granular hydroxyapatite is different according to a region to be used but hydroxyapatite having a particle size of 0.1-5mm, pref., 0.2-3mm is suitably used. A calcium phosphate mixture prepared by mixing powdery tetracalcium phosphate and powdery calcium phosphate whose Ca/Pmol ratio is below 1.67 so as to adjust a Ca/P mol ratio to 1.3-1.8 is pref. added to 100 pts.wt. of granular hydroxyapatite in an amount of 10-500 pts.wt. further pref., 20-200 pts.wt. When the addition amount of the calcium phosphate is too little, sufficient curing is not generated and, when too much, not only operability at a filling time is inferior but also the shape of a filling part can not be held.
Testosterone gel, for topical use is a clear to translucent hydroalcoholic topical gel containing testosterone, an androgen. Testosterone gel provides continuous transdermal delivery of testosterone for 24 hours, following a single application to intact, clean, dry skin of the shoulders and/or upper arms. 

Testosterone gel is available in unit-dose tubes, unit-dose packets, and a metered-dose pump. One 5-g or two 5-g tubes/packets of testosterone gel contains 50 mg or 100 mg of testosterone, respectively. One pump actuation dispenses 1.25 g of gel, which contains 12.5 mg of testosterone. Four pump actuations or eight pump actuations contain 50 mg or 100 mg of testosterone, respectively. Each metered-dose pump container is capable of dispensing 60 pump actuations. 

The active pharmacological ingredient in testosterone gel is testosterone. Testosterone USP is a white to practically white crystalline powder chemically described as 17-β hydroxyandrost-4-en-3-one. The structural formula is shown in the following figure:

Testosterone (C19H28O2) MW: 288.42

Inactive ingredients in testosterone gel are carbomer copolymer Type B, carbomer homopolymer Type C, diisopropyl adipate, ethyl alcohol, glycerin, methyl laurate, oleyl alcohol, polyethylene glycol, propylene glycol, purified water, and tromethamine.
The placebo gel (PG) will be applied to the buccal surfaces of the central and lateral incisors, canines and upper and lower premolars, with a microbrush actively, for 10 minutes. Subsequently, all groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whiteness HP, FGM). Sensitivity assessment will be carried out using a form consisting of a visual analogue scale (VAS), patients will be instructed to record tooth sensitivity daily, during the 21 days of follow-up. To measure color, the VITA Easyshade spectrophotometer (VITA, Germany)) will be used at two times: baseline (Ti) and one week after the 3rd bleaching session (Tf).
INTRODUCTION: Extra-articular hip resection may be necessary in cases of malignant tumour of the pelvic bone or of the proximal femur invading the hip joint. When the tumour is in the proximal femur, it is possible to resect the acetabulum en bloc by performing a periacetabular osteotomy, but this creates a discontinuity in the pelvic ring with difficult reconstruction and diminished function. Several techniques described recently seek to be as sparing as possible on the pelvic bone by preserving the posterior column or both columns in order to facilitate reconstruction and improve function. However, these still require complex reconstructions and can necessitate intra-pelvic dissection.
TECHNIQUE: We describe here an extra-articular hip resection technique for tumours of the proximal femur invading the joint, with maintenance of pelvic continuity by preserving both columns and the quadrilateral plate of the acetabulum, without intra-pelvic dissection, that can be performed on patients in whom the medial wall of the acetabulum is thick enough. Our preliminary assessments have included studies on dry bone and imaging analyses. The technique was first tested on a single cadaver pelvis (encompassing 2 hips) and subsequently performed on a patient with a pathological fracture of the femoral neck due to osteosarcoma secondary to Paget's disease.
CONCLUSIONS: Further clinical applications are essential to evaluate the overall effectiveness, safety and impact on patient functionality of this experimental technique.
In every cluster designated as an intervention group, patients aged 65 or older will be selected according to the inclusion criteria. Within this group, high-risk patients will be identified using the CHARGE-AF score, and will be prescribed the FibriCheck® app.
Spatial localization is important for social interaction and safe mobility, and relies heavily on vision and hearing. While people with vision or hearing impairment compensate with their intact sense, people with dual sensory impairment (DSI) may require rehabilitation strategies that take both impairments into account. There is currently no tool for assessing the joint effect of vision and hearing impairment on spatial localization in this large and increasing population. To this end, we developed a novel Dual Sensory Spatial Localization Questionnaire (DS-SLQ) that consists of 35 everyday spatial localization tasks. The DS-SLQ asks participants about their difficulty completing different tasks using only vision or hearing, as well as the primary sense they rely on for each task. We administered the DS-SLQ to 104 participants with heterogenous vision and hearing status. Rasch analysis confirmed the psychometric validity of the DS-SLQ and the feasibility of comparing vision and hearing spatial abilities in a unified framework. Vision and hearing impairment were associated with decreased visual and auditory spatial abilities. Differences between vision and hearing abilities predicted overall sensory reliance patterns. In DSI rehabilitation, DS-SLQ may be useful for measuring vision and hearing spatial localization abilities and predicting the better sense for completing different spatial localization tasks.
The invention relates to protein LppQ of Mycoplasma mycoides subsp. mycoides SC, DNA encoding said protein, processes for the preparation of the protein and the DNA, a vector comprising the DNA, a host cell comprising the vector, use of the protein in immunological methods for the detection of M. mycoides subsp. Mycoides SC, use of the DNA in genetic methods for the detection of M. mycoides subsp. mycoides SC, use of the protein and DNA for preparing a vaccine against M. mycoides subsp. mycoides, processes for the immunological detection of antibodies directed to M. mycoids subsp. Mycoides SC and PCR process for the detection of M. mycoides subsp. mycoides SC, a monoclonal antibody specific for LppQ or parts thereof and a diagnostic kit for the detection of an infection with Mycoplasma mycoides subsp. mycoides SC.
A dissolving gingival retraction cord apparatus for minimizing gum irritation includes a container body having a container bottom side, a container sidewall, and an open container top side defining a container inside. A gel solution is coupled within the container body. A lid is coupled to the container body with a dispense aperture extending therethrough. A spool is coupled to the lid and is submerged within the gel solution when the lid is engaged with the container body. A retraction cord is windingly coupled around the spool and has a cord distal end extending through the dispense aperture of the lid. The retraction cord absorbs, or is coated with, the gel solution. The retraction cord is dissolvable after installation within a person's gum tissue.
Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
The worldwide HIV/AIDS epidemic may only be controlled through development and utilization of a safe and effective vaccine that will prevent HIV infection. To fill gaps in the understanding of HIV vaccines, studies of mucosal immunity aim to complement assessments of systemic immunity. Yet it is unclear, and important to understand, how mucosal collections and the kinetics of immune activation they might initiate may impact peripheral blood endpoints in HIV vaccine trials. The HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID) are conducting a single-site, exploratory cohort study evaluating the feasibility of sampling mucosa and assessing cellular immune responses in sexually active men who have sex with men, a population in which later-phase HIV vaccine clinical trials are often conducted.

The primary purpose of HVTN 914 is to assess the feasibility of performing safe and tolerable circumcision and rectosigmoid biopsy studies on a study population of 30 healthy, HIV-seronegative, uncircumcised men in Lima, Peru, aged 21 to 30 years, who have sex with men and who are at high risk for acquisition of HIV; to assess institutional capacities to process mucosal samples; and to identify methods of evaluating foreskin and rectosigmoid mucosal immune responses that provide minimal variability for analysis of small sample sizes.

The study is designed to mimic an HIV vaccine study mucosal collection protocol. Participants agree to elective sigmoidoscopy biopsy collections and circumcision, and actively participate in this study for approximately 7 months. The primary analysis will focus on pre- and post-procedure retention, safety laboratory values, sexual satisfaction, HIV risk behaviors, and levels of activation markers associated with vulnerability to HIV infection in samples of peripheral blood mononuclear cells. A total of 11 study visits (including a screening visit) occur at Weeks 0-5, 10, and 26-28. Study procedures include physical exams, blood and urine collection, HIV testing, and questionnaire. Elective rectosigmoid bioscopy is performed at Weeks 2 and 27. Elective circumcision is performed at Week 4. Some blood collected from participants will be stored and used in future research. Risk-reduction counseling will be conducted at all study visits.
Patients with KRAS mutant tumors. Patients received AUY922 at 70 mg/m\^2 weekly infusions.
MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
Older adults with cancer are at risk of over-treatment or under-treatment, and treatment decision-making is difficult due to both the complexity of adverse aging and under-representation in clinical trials. It is recommended to perform a frailty assessment before treatment decision-making. Although the importance of radiotherapy increases in geriatric oncology, there is less evidence base information on frailty assessment in radiation oncology than in medical/surgical oncology. The present literature review analyzed the available data regarding frailty assessment tools in geriatric radiation oncology. The predictive value of geriatric assessment on survival outcomes has been shown in many cancer subtypes treated with radiotherapy. Additionally, the Geriatric-8 score is the most evidenced screening tool in frailty assessment. However, researches are ongoing on the cut-off points of geriatric screening tools and which one is the best. Prospective randomized controlled trials are required for the integration of geriatric screening tools and geriatric assessment-driven interventions into geriatric radiation oncology practice.
Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.